Table 1.

Principal characteristics of the studies included in the meta-analysis.

Study ID	Sample size(T/C)/case	Age (mean ± SD)		Stage	Intervention		Cinobufacini dose	Duration(day)	Outcome
		Test group	Control group		Test group	Control group
Su [22]	44/44	56.48 ± 7.05	55.74 ± 6.12	IIIb, IV	DP + cinobufacini	DP	0.6 g·bid·po	84	①④⑤⑥
Li [23]	21/18	——	——	IIIb, IV	DP + cinobufacini	DP	0.75 g·tid·po	90	②
Chen et al. [24]	36/31	54.26 ± 10.38	53.45 ± 11.69	III, IV	GP + cinobufacini	GP	0.5 g·tid·po	84	①②③④⑤⑥⑦
Li [25]	38/37	60.09 ± 4.81	58.97 ± 4.63	III, IV	DP + cinobufacini	DP	0.5 g·tid·po	42	①⑥⑦
Huang [26]	43/43	61.58 ± 7.26	61.23 ± 7.15	IIIb, IV	GP + cinobufacini	GP	0.5 g·bid·po	42	①⑥⑦
Li et al. [23]	58/58	56.38 ± 8.24	57.12 ± 8.44	IIIb, IV	GP + cinobufacini	GP	0.5 g·bid·po	84	①③⑥⑦
Lan et al. [27]	43/42	55.63 ± 12.05	56.49 ± 11.61	III, IV	TC + cinobufacini	TC	0.5 g·tid·po	63	①
Chen et al. [28]	31/31	55.87 ± 6.58	56.29 ± 6.49	IIIb, IV	GP/AP + cinobufacini	GP/AP	0.5 g·tid·po	42	①⑤⑥⑦
Yu et al. [29]	33/30	——	——	III, IV	GP + cinobufacini	GP	0.5 g·tid·po	42	①④⑤⑥
Liu [30]	40/40	67.88 ± 2.27	68.54 ± 2.11	IIIb, IV	TP/NP + cinobufacini	TP/NP	0.6 g·bid·po	42	②④⑤⑥
Chen et al. [31]	36/36	56.90 ± 11.00	56.20 ± 10.70	IIIb, IV	TC + cinobufacini	TC	0.5 g·tid·po	84	①⑦
Pu et al. [32]	42/38	54.60 ± 9.38	57.83 ± 12.42	III, IV	GP + cinobufacini	GP	0.5 g·bid·po	42	①②③⑥⑦
Shi [33]	51/51	——	——	III, IV	TP + cinobufacini	TP	0.6 g·tid·po	42	①②④⑤⑥
Wei and Xu [34]	34/34	57.39 ± 4.31	58.31 ± 2.57	III, IV	GP + cinobufacini	GP	0.5 g·tid·po	42	①④⑥
Chen et al. [35]	40/40	59.30 ± 7.90	59.50 ± 7.50	IIIb, IV	GP + cinobufacini	GP	0.6 g·tid·po	42	①②③
Li et al. [36]	63/63	58.73 ± 9.54	57.96 ± 9.86	IIIb, IV	DP + cinobufacini	DP	0.5 g·tid·po	105	①②③④⑤⑥
Xiao et al. [37]	68/62	——	——	IV	GP + cinobufacini	GP	0.5 g·tid·po	42	①
Liu [38]	45/40	——	——	III, IV	NP/TP + cinobufacini	NP/TP	0.5 g·bid·po	42	①②③④⑤⑥
Miao et al. [39]	30/30	58.00 ± 7.00	57.00 ± 6.50	IIIb, IV	TP + cinobufacini	TP	0.5 g·tid·po	84	①④⑥

Note. (1) T is the test group; C is the control group; AP: pemetrexed + cisplatin; DP: docetaxel + cisplatin; GP: gemcitabine + cisplatin; NP: vinorelbine + cisplatin; TC: paclitaxel + carboplatin; TP: paclitaxel + cisplatin; (2) outcome index: ① ORR; ② one-year survival rate; ③ two-year survival rate; ④ leukocyte toxicity; ⑤ platelet toxicity; ⑥ vomiting reaction; ⑦ immune response.